Business Context and Reporting Period
This Form 8-K reports the consummation of a merger between Graphite Bio, Inc. and LENZ Therapeutics Operations, Inc. (LENZ OpCo) on March 21, 2024. Following the transaction, Graphite Bio changed its name to LENZ Therapeutics, Inc. ("LENZ" or the "Company") and effected a 1:7 reverse stock split. The Company is a late-stage biopharmaceutical firm focused on developing treatments for presbyopia, specifically the product candidates LNZ100 and LNZ101. The reporting period covers the closing of the merger and the financial position of LENZ OpCo as of December 31, 2023.
Key Financial Metrics
Revenue and Profitability: LENZ OpCo generated no revenue for the year ended December 31, 2023, compared to $15.0 million in license revenue in 2022. The Company reported a net loss of $69.97 million for 2023, a significant increase from the $10.81 million net loss in 2022. As of December 31, 2023, the accumulated deficit was $95.2 million.
Cash Flow and Liquidity: As of December 31, 2023, LENZ OpCo held $65.8 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities was $60.4 million in 2023. The Company raised approximately $53.5 million through a PIPE financing concurrent with the merger.
Capital Structure: Immediately following the merger, there were approximately 25.5 million shares of Common Stock outstanding. The PIPE Investors purchased 3,559,565 shares at $15.03 per share.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped 100% to zero in 2023, as the $15.0 million license revenue recognized in 2022 from the Ji Xing agreement was a one-time event.
- Expense Surge: Operating expenses increased 184% to $72.4 million in 2023 from $25.5 million in 2022. Research and Development (R&D) expenses rose 182% to $59.5 million, driven primarily by the CLARITY Phase 3 clinical trials. Selling, General, and Administrative (SG&A) expenses increased 197% to $12.9 million, largely due to legal fees associated with an abandoned IPO and increased headcount.
- Corporate Structure: The Company transitioned from a private operating subsidiary (LENZ OpCo) to a public entity (LENZ Therapeutics, Inc.) via a reverse merger with Graphite Bio, Inc.
Guidance, Outlook, and Risks
Clinical Outlook: The Company expects to announce top-line results from its three Phase 3 CLARITY trials in April 2024. Subject to successful results, an NDA submission to the FDA is planned for mid-2024, with a target commercial launch in the second half of 2025.
Liquidity Outlook: Management believes that existing cash resources combined with the merger and PIPE proceeds will fund operations through at least 2026, contingent on successful trial completion and regulatory approval.
Risks and Contingencies:
- Legal Proceedings: Two shareholder lawsuits have been filed challenging the merger disclosures, alleging misrepresentations regarding financial projections and advisor conflicts. The Company intends to vigorously defend these claims.
- Regulatory Risk: Future revenue is entirely dependent on FDA approval of LNZ100 or LNZ101. Failure in Phase 3 trials or regulatory rejection would materially impact the business.
- Capital Needs: While current funds are projected to last through 2026, the Company may require additional financing sooner if clinical timelines extend or commercialization costs exceed expectations.
Investor Verification Checklist
- Verify the April 2024 announcement of Phase 3 CLARITY trial results to confirm efficacy and safety endpoints.
- Monitor the status of the pending shareholder litigation regarding merger disclosures.
- Confirm the timeline for the NDA submission to the FDA in mid-2024.
- Review the pro forma financial information (Exhibit 99.2) to understand the combined entity's capital position post-merger.
- Assess the competitive landscape, specifically the market performance of AbbVie's Vuity, the only currently approved pharmaceutical treatment for presbyopia.